CSL312 (garadacimab) in the prevention of hereditary angioedema attacks

Trial Identifier: CSL312_3001
Sponsor: CSL Behring
Start Date: January 2021
Primary Completion Date: June 2022
Study Completion Date: June 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Alberta Edmonton, Alberta, Canada, T6G 2B7
Canada, Ontario Ottawa, Ontario, Canada, K1H 1E4
Canada, Ontario Toronto, Ontario, Canada, M3B 3S6
Canada, Québec Québec, Canada, G1V 4W2
Germany Berlin, Germany, 10117
Germany Leipzig, Germany, 04103
Germany Mainz, Germany, 55131
Germany Mörfelden-Walldorf, Germany, 64546
Germany, Hessen Frankfurt, Hessen, Germany, 60590
Hungary Budapest, Hungary, 1088
Israel Ashkelon, Israel, 7830604
Japan Saitama, Japan, 340-0041
Japan, Hiroshima Hiroshima-shi, Hiroshima, Japan, 734-8551
Japan, Hyogo Kobe-shi, Hyogo, Japan, '650-0017
Japan, Kanagawa Kawasaki-shi, Kanagawa, Japan, 216-8511
Japan, Kawagoe-shi Saitama, Kawagoe-shi, Japan, 350-8550
Japan, Saga-shi Saga, Saga-shi, Japan, '849-8501
Japan, Shizuoka Yaizu-shi, Shizuoka, Japan, 425-0088
Japan, Tokyo Bunkyo, Tokyo, Japan, 113-8431
Netherlands Amsterdam, Netherlands, 1105 AZ
United States, Alabama Birmingham, Alabama, United States, 35209
United States, Arizona Scottsdale, Arizona, United States, 85251
United States, California Santa Monica, California, United States, 90404
United States, California Walnut Creek, California, United States, 94598
United States, Maryland Chevy Chase, Maryland, United States, 20815
United States, Ohio Cincinnati, Ohio, United States, 45231
United States, Pennsylvania Hershey, Pennsylvania, United States, 17033
United States, Texas Dallas, Texas, United States, 75231